RecruitingPhase 1Phase 2NCT06921928
Study for AZD4360 in Participants With Advanced Solid Tumours
A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD4360 in Adult Participants With Advanced Solid Tumours
Sponsor
AstraZeneca
Enrollment
117 participants
Start Date
Apr 29, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic solid tumours selected for expression of CLDN18.2.
Eligibility
Min Age: 18 YearsMax Age: 130 Years
Inclusion Criteria8
- Participant must be ≥ 18 at the time of signing the ICF.
- Eastern cooperative oncology group performance status of 0-1 with no deterioration over the previous 2 weeks prior to baseline or day of first dosing.
- Minimum life expectancy of 12 weeks in the opinion of the Investigator.
- Adequate organ and marrow function, as defined by protocol.
- \. Contraceptive use by men or women should be consistent with local regulations, as defined by protocol.
- \. Histologically confirmed advanced or metastatic Pancreatic ductal adenocarcinoma (PDAC), Gastric or Gastroesophageal junction cancer (G/GEJC), and Biliary tract cancer (BTC) with documented positive CLDN18.2 expression.
- \. Participants must have received at least one prior line of systemic therapy in the advanced/metastatic disease.
- \. At least one measurable lesion according to RECIST v1.1.
Exclusion Criteria11
- Human Epidermal Growth Factor Receptor 2 (HER2) positive (3+ by IHC or 2+ by IHC and positive by in situ hybridisation) or indeterminate G/GEJC participants.
- Unstable or active peptic ulcer disease or digestive tract bleeding including but not limited to clinically significant bleeding in the setting of prior CLDN18.2 directed therapy.
- Participants with clinically significant ascites that require drainage.
- Central nervous system (CNS) metastases or CNS pathology, as defined by protocol.
- With spinal cord compression or with high risk of paralysis.
- History of non-infectious interstitial lung disease/pneumonitis.
- Participant has cardiac abnormalities, as defined by protocol.
- History of another primary malignancy within 2 years prior to screening.
- Known serologic status reflecting active hepatitis B or hepatitis C.
- Known HIV infection that is not well controlled.
- Active tuberculosis infection.
Interventions
DRUGAZD4360
Antibody-Drug Conjugate targeting Claudin 18.2 (CLDN18.2)
Locations(17)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06921928
Related Trials
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
NCT051871821 location
Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma
NCT072774391 location
Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
NCT066480571 location
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
NCT0697316127 locations
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT0570222944 locations